Founded in 2019, ADARx Pharmaceuticals, Inc. located in San Diego, is a clinical-stage biotech with a proprietary siRNA platform for silencing or editing target mRNA in genetic, cardiovascular, complement-mediated and central nervous system diseases. Led by CEO Dr. Zhen Li, ADARx raised a $46m Series B-1 round in January, 2023. led by Ascenta. and also a $200m Series C round in August 2023 co-led by Bain Capital Life Sciences and TCGx (with participation by Ascenta).